Carmen Calfa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carmen Calfa has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas A. Borja
John T. Macdonald Foundation Department of Human Genetics University of Miami Miller School of Medicine Miami Florida USA
18 shared publications - Daniel A. Sussman
Division of Digestive Health and Liver Diseases, Miller School of Medicine, University of Miami, Miami, Florida
17 shared publications - Mustafa Tekin
John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA
17 shared publications - Rachel Silva-Smith
Dr. John T. Macdonald Foundation Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, Florida
17 shared publications - Elizabeth Garrett-Mayer
American Society of Clinical Oncology, Alexandria, VA
5 shared publications - Pam K. Mangat
American Society of Clinical Oncology, Alexandria, VA
5 shared publications
Latest Publications
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
Beliefs about Hereditary Susceptibility to Cancer and Desire to Know about a Genetic Predisposition: An Analysis of the NCI Health Information National Trends Survey
Background: This study characterized beliefs about hereditary susceptibility to cancer and desire to know about a genetic predisposition to cancer in a nationally representative survey of US adults. Methods: Adjusted regression models using weighted survey analysis of NCI HINTS 2020 data assessed predictors of how much respondents (1) believe genes that are inherited determine whether a person will develop cancer and (2) would want to know if they had a genetic change that increases their chance of getting cancer. Results: On average, respondents endorsed between “somewhat” and “a lot” for how much hereditary susceptibility determines cancer risk. Respondents believed that hereditary susceptibility to cancer, cardiovascular disease, and diabetes were similar (Means= 1.83-1.85, all p>0.6). Individuals who had health insurance (β=–0.42 - –0.37, p=0.017-0.021) and previously sought cancer information (β=–0.19, p<0.001) believed in greater hereditary susceptibility to cancer, whereas those who self-reported good health believed in less hereditary susceptibility to cancer (β=0.16, p=0.022). Individuals who believed in greater hereditary susceptibility to cancer (β=0.14, p=0.001), previously sought cancer information (β=–0.19, p=0.002), had a family history of cancer (β=–0.19, p=0.005), were less fatalistic (β=–0.08, p=0.036), and were Hispanic (β=–0.25, p=.009) or Black (β=–0.47, p<0.001) endorsed a greater desire to know about a genetic predisposition to cancer. Conclusions: Efforts are needed to improve understanding of hereditary susceptibility, address fatalistic beliefs and misinformation, facilitate disclosure of family cancer history indicative of a potential genetic predisposition to cancer. Impact: Efforts are needed to improve access to genetic counseling and testing through education and targeted interventions.
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
Beliefs about Hereditary Susceptibility to Cancer and Desire to Know about a Genetic Predisposition: An Analysis of the NCI Health Information National Trends Survey
Background: This study characterized beliefs about hereditary susceptibility to cancer and desire to know about a genetic predisposition to cancer in a nationally representative survey of US adults. Methods: Adjusted regression models using weighted survey analysis of NCI HINTS 2020 data assessed predictors of how much respondents (1) believe genes that are inherited determine whether a person will develop cancer and (2) would want to know if they had a genetic change that increases their chance of getting cancer. Results: On average, respondents endorsed between “somewhat” and “a lot” for how much hereditary susceptibility determines cancer risk. Respondents believed that hereditary susceptibility to cancer, cardiovascular disease, and diabetes were similar (Means= 1.83-1.85, all p>0.6). Individuals who had health insurance (β=–0.42 - –0.37, p=0.017-0.021) and previously sought cancer information (β=–0.19, p<0.001) believed in greater hereditary susceptibility to cancer, whereas those who self-reported good health believed in less hereditary susceptibility to cancer (β=0.16, p=0.022). Individuals who believed in greater hereditary susceptibility to cancer (β=0.14, p=0.001), previously sought cancer information (β=–0.19, p=0.002), had a family history of cancer (β=–0.19, p=0.005), were less fatalistic (β=–0.08, p=0.036), and were Hispanic (β=–0.25, p=.009) or Black (β=–0.47, p<0.001) endorsed a greater desire to know about a genetic predisposition to cancer. Conclusions: Efforts are needed to improve understanding of hereditary susceptibility, address fatalistic beliefs and misinformation, facilitate disclosure of family cancer history indicative of a potential genetic predisposition to cancer. Impact: Efforts are needed to improve access to genetic counseling and testing through education and targeted interventions.
- 7 January 2026
- Published by Oxford University Press (OUP) in Translational Behavioral Medicine
- Vol. 16 (1)
The potential of AI for adjunctive supportive care in cancer survivorship: opportunities, challenges, and the PRECISION-AI practical framework
Among the 18 million cancer survivors in the United States, many report significant unmet physical, psychosocial, and practical needs that existing healthcare systems struggle to address at scale. This conceptual perspective examines how artificial intelligence (AI)-powered platforms can serve as adjuncts to care by addressing unmet needs, supporting symptom management, and delivering psychoeducation and psychosocial support. Drawing on evidence from oncology AI and cancer survivorship, we consider how AI may improve the quality, personalization, and accessibility of care, distinguishing applications supported by prospective evidence from those that remain in early stages. Preliminary evidence suggests AI has the potential to deliver personalized psychoeducation, symptom monitoring, and psychosocial support as adjuncts to clinical care. To guide responsible development and implementation of these tools, we propose the PRECISION-AI Adjunctive Supportive Care Development Framework, a systematic model for developing, validating, and implementing AI in supportive oncology care. As a primary case example, we describe My Wellness Support, an agentic AI-enabled, risk-stratified supportive care platform designed to augment standard survivorship care, including its conceptual framework and development, ethical considerations, data protections, transparency, and bias mitigation. A proof-of-concept study in breast cancer patients is currently underway. Outcome data are not yet available, and no effectiveness or safety claims are made for the platform. AI in cancer survivorship has potential to expand access to survivorship support and improve health-related quality of life, but realizing this potential requires rigorous prospective validation, equitable implementation across diverse populations, and sustained collaboration among healthcare providers, developers, survivors, ethicists, and policymakers.
- 7 January 2026
- Published by Oxford University Press (OUP) in Translational Behavioral Medicine
- Vol. 16 (1)
The potential of AI for adjunctive supportive care in cancer survivorship: opportunities, challenges, and the PRECISION-AI practical framework
Among the 18 million cancer survivors in the United States, many report significant unmet physical, psychosocial, and practical needs that existing healthcare systems struggle to address at scale. This conceptual perspective examines how artificial intelligence (AI)-powered platforms can serve as adjuncts to care by addressing unmet needs, supporting symptom management, and delivering psychoeducation and psychosocial support. Drawing on evidence from oncology AI and cancer survivorship, we consider how AI may improve the quality, personalization, and accessibility of care, distinguishing applications supported by prospective evidence from those that remain in early stages. Preliminary evidence suggests AI has the potential to deliver personalized psychoeducation, symptom monitoring, and psychosocial support as adjuncts to clinical care. To guide responsible development and implementation of these tools, we propose the PRECISION-AI Adjunctive Supportive Care Development Framework, a systematic model for developing, validating, and implementing AI in supportive oncology care. As a primary case example, we describe My Wellness Support, an agentic AI-enabled, risk-stratified supportive care platform designed to augment standard survivorship care, including its conceptual framework and development, ethical considerations, data protections, transparency, and bias mitigation. A proof-of-concept study in breast cancer patients is currently underway. Outcome data are not yet available, and no effectiveness or safety claims are made for the platform. AI in cancer survivorship has potential to expand access to survivorship support and improve health-related quality of life, but realizing this potential requires rigorous prospective validation, equitable implementation across diverse populations, and sustained collaboration among healthcare providers, developers, survivors, ethicists, and policymakers.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 5: Summary of the hereditary cancer germline sequencing performed for each patient in the MPC cohort
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 5: Summary of the hereditary cancer germline sequencing performed for each patient in the MPC cohort
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 1: Summary of occupational exposures and modifying chronic health conditions in the MPC patient cohort
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 1: Summary of occupational exposures and modifying chronic health conditions in the MPC patient cohort
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 6: Sensitivity analysis comparing treatment received for each cancer diagnosis, with the exclusion of all skin cancer cases.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 6: Sensitivity analysis comparing treatment received for each cancer diagnosis, with the exclusion of all skin cancer cases.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Figure 1: Flow diagram of patients evaluated with the selection criteria sequentially applied in order to define the triple primary cancer cohort for further analysis.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Figure 1: Flow diagram of patients evaluated with the selection criteria sequentially applied in order to define the triple primary cancer cohort for further analysis.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 6: Sensitivity analysis comparing treatment received for each cancer diagnosis, with the exclusion of all skin cancer cases.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 6: Sensitivity analysis comparing treatment received for each cancer diagnosis, with the exclusion of all skin cancer cases.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 4: Number of genes tested over time in the MPC patient cohort and its effect on hereditary cancer sequencing results
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 4: Number of genes tested over time in the MPC patient cohort and its effect on hereditary cancer sequencing results
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 1: Summary of occupational exposures and modifying chronic health conditions in the MPC patient cohort
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 1: Summary of occupational exposures and modifying chronic health conditions in the MPC patient cohort
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 5: Summary of the hereditary cancer germline sequencing performed for each patient in the MPC cohort
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Triple Primary Cancers: An Analysis of Genetic and Environmental Factors
Supplementary Table 5: Summary of the hereditary cancer germline sequencing performed for each patient in the MPC cohort